Glimaryl 2mg Tablet

Glimepiride 2mg

Hypersensitivity; sulfa allergy
Type 1 diabetes
Diabetic ketoacidosis (with or without coma)
Complicated gestational diabetes mellitus

Patients with risk of severe hypoglycemia: Elderly, debilitated, or malnourished; adrenal or pituitary insufficiency; patients with stress due to infection, fever, trauma, or surgery
If patient is exposed to stress, it may be necessary to discontinue glimepiride and initiate insulin
Use caution in hepatic/renal impairment
Pregnancy, lactation
Increased risk of cardiovascular mortality
Persons allergic to other sulfonamide derivatives may develop allergic reaction to glimepiride
Hypoglycemia may be difficult to recognize in patients with autonomic neuropathy
Hemolytic anemia may occur with glucose 6-phosphate dehydrogenase (G6PD) deficiency when treated with sulfonylurea agents
Fluid retention, which may exacerbate or lead to heart failure, may occur
Combination use with insulin and use in congestive heart failure NYHA Class I and II may increase risk of other cardiovascular effects
Potential risk of ischemic cardiovascular (CV) events relative to placebo reported in meta-analysis studies, but not confirmed in long-term CV outcome trial versus metformin or sulfonylurea
Dose-related edema, weight gain, and anemia may occur
Macular edema reported
Increased incidence of bone fracture reported
Postmarketing reports for glimepiride include anaphylaxis, angioedema, and Stevens-Johnson syndrome; promptly discontinue glimepiride, assess for other causes, institute appropriate monitoring and treatment, and initiate alternative treatment for diabetes

Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use Glimaryl 2mg Tablet only for the indication prescribed.